A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies-Reference-Cited by-同舟云学术

A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies

Published:2020-05-07 Issue:6 Volume:37 Page:2853-2864
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Mitani Seiichiro,Kadowaki Shigenori^ORCID,Komori Azusa,Kondoh Chihiro,Oze Isao,Kato Kyoko,Masuishi Toshiki,Honda Kazunori,Narita Yukiya,Taniguchi Hiroya,Ando Masashi,Tanaka Tsutomu,Tajika Masahiro,Muro Kei

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-020-01358-2.pdf

Reference24 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386386. https://doi.org/10.1002/ijc.29210.

2. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (5th edition). Gastric Cancer. 2020. https://doi.org/10.1007/s10120-020-01042-y.

3. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS SSO and TOS. Ann Oncol. 2019;30:19–33. https://doi.org/10.1093/annonc/mdy502.

4. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5.

5. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4:e180013. https://doi.org/10.1001/jamaoncol.2018.0013.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-Fluorouracil plus L-leucovorin and oxaliplatin treatment for esophageal squamous cell carcinoma: A multicenter retrospective study;2024-06-11

2. Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study;ESMO Open;2023-12

3. Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences;Gastric Cancer;2022-06-11

4. Efficacy and Safety of FOLFOX in Advanced Gastric Cancer Initially Presenting With Disseminated Intravascular Coagulation;In Vivo;2022

5. Current state of chemotherapy and immunotherapy regimens in gastric cancer;Research and Clinical Applications of Targeting Gastric Neoplasms;2021